Abstract
SOLAR-1 investigated use of ALP+FLV in patients (pts) with HR+/HER2-, PIK3CA-mutated ABC after progression on endocrine-based therapy. SOLAR-1 demonstrated a clinically significant increase in all-grade (G) and G3-4 HG compared to placebo+FLV. Current guidance recommends an insulin sensitizer (metformin, thiazolidinedione, DPP-4 inhibitor) at HG onset. Given high rates of HG, a preventative protocol and ID of associated RFs was implemented to minimize HG, dose reductions and discontinuation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
